GlassScriptPhysician profile
Richard N Sabinsky
NPI 1184614596
$7,818.04
in general payments reported to CMS, 2019-2025
39 companies · $927 in 2025
The $927 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,069 · 2020: $1,216 · 2021: $1,408 · 2022: $1,399 · 2023: $959 · 2024: $839 · 2025: $927.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,726.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,153.67 | 2019-2025 | Trelegy Ellipta |
| Abbvie INC. | $957.12 | 2019-2025 | Ubrelvy, Synthroid |
| Amgen INC. | $728.04 | 2019-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $670.52 | 2020-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $538.28 | 2019-2023 | Tradjenta, Jardiance, Spiriva Respimat |
| Astrazeneca Pharmaceuticals LP | $423.02 | 2019-2025 | Farxiga, Airsupra |
| Pfizer INC. | $418.00 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $355.61 | 2019-2025 | Gardasil 9, Capvaxive |
| Lilly USA, LLC | $350.34 | 2019-2025 | Jardiance, Emgality, Zepbound |
| Regeneron Healthcare Solutions, INC. | $295.35 | 2019-2025 | Dupixent, Evkeeza |
| Amarin Pharma, INC. | $259.85 | 2019-2022 | |
| Genzyme Corporation | $239.23 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $172.79 | 2019-2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $136.60 | 2023-2025 | Xifaxan, Trulance |
| Horizon Therapeutics Plc | $136.09 | 2019-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Sabinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.